SCOPUS 정보 검색 플랫폼

Volumn 117, Issue 16, 2011, Pages 3758-3762

Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression

(8) Shah, Jatin a Bladé, Joan b Sonneveld, Pieter c Harousseau, Jean Luc d Lantz, Keith e Londhe, Anil e Lowery, Colin e Orlowski, Robert Z a

a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER (United States)

b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS (Spain)

c ERASMUS MEDICAL CENTER (Netherlands)

d HÔTEL DIEU (France)

e CENTOCOR INC (United States)

Author keywords

bortezomib; monoclonal (M) protein; pegylated liposomal doxorubicin; relapsed refractory multiple myeloma; response rapidity

Indexed keywords

BORTEZOMIB; DOXORUBICIN; M PROTEIN;

ALOPECIA; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RELAPSE; CONTROLLED STUDY; DRUG SAFETY; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; STOMATITIS; THROMBOEMBOLISM; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DISEASE PROGRESSION; DOXORUBICIN; HUMANS; MULTIPLE MYELOMA; MYELOMA PROTEINS; POLYETHYLENE GLYCOLS; PYRAZINES; RECURRENCE;

EID: 80051548597 PISSN: 0008543X EISSN: 10970142 Source Type: Journal
DOI: 10.1002/cncr.25937 Document Type: Article

Times cited : (21)

References (12)

1
- 77955635233
- Cancer statistics, 2010
- Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60: 277-300.
- (2010) CA Cancer J Clin. , vol.60 , pp. 277-300
- Jemal, A.¹ Siegel, R.² Xu, J.³ Ward, E.⁴

2
- 33644877198
- New approaches to treatment for multiple myeloma: Durable remission and quality of life as primary goals
- Durie BG,. New approaches to treatment for multiple myeloma: durable remission and quality of life as primary goals. Clin Lymphoma Myeloma. 2005; 6: 181-190.
- (2005) Clin Lymphoma Myeloma. , vol.6 , pp. 181-190
- Durie, B.G.¹

3
- 0037216353
- Review of 1027 patients with newly diagnosed multiple myeloma
- Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003; 78: 21-33. (Pubitemid 36033957)
- (2003) Mayo Clinic Proceedings , vol.78 , Issue.1 , pp. 21-33
- Kyle, R.A.¹ Gertz, M.A.² Witzig, T.E.³ Lust, J.A.⁴ Lacy, M.Q.⁵ Dispenzieri, A.⁶ Fonseca, R.⁷ Rajkumar, S.V.⁸ Offord, J.R.⁹ Larson, D.R.¹⁰ Plevak, M.E.¹¹ Therneau, T.M.¹² Greipp, P.R.¹³

4
- 34548539381
- Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: Combination therapy improves time to progression
- DOI 10.1200/JCO.2006.10.5460
- Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007; 25: 3892-3901. (Pubitemid 47477266)
- (2007) Journal of Clinical Oncology , vol.25 , Issue.25 , pp. 3892-3901
- Orlowski, R.Z.¹ Nagler, A.² Sonneveld, P.³ Blade, J.⁴ Hajek, R.⁵ Spencer, A.⁶ San Miguel, J.⁷ Robak, T.⁸ Dmoszynska, A.⁹ Horvath, N.¹⁰ Spicka, I.¹¹ Sutherland, H.J.¹² Suvorov, A.N.¹³ Zhuang, S.H.¹⁴ Parekh, T.¹⁵ Xiu, L.¹⁶ Yuan, Z.¹⁷ Rackoff, W.¹⁸ Harousseau, J.-L.¹⁹

5
- 34247846013
- Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma
- DOI 10.1111/j.1365-2141.2007.06585.x
- Richardson PG, Sonneveld P, Schuster MW, et al. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol. 2007; 137: 429-435. (Pubitemid 46698286)
- (2007) British Journal of Haematology , vol.137 , Issue.5 , pp. 429-435
- Richardson, P.G.¹ Sonneveld, P.² Schuster, M.W.³ Irwin, D.⁴ Stadtmauer, E.A.⁵ Facon, T.⁶ Harousseau, J.-L.⁷ Ben-Yehuda, D.⁸ Lonial, S.⁹ San Miguel, J.-F.¹⁰ Cavenagh, J.D.¹¹ Anderson, K.C.¹²

6
- 8344251663
- Assessment of early paraprotein response to vincristine-doxorubicin- dexamethasone chemotherapy may help guide therapy in multiple myeloma
- DOI 10.1111/j.1445-5994.2004.00689.x
- Ross DM, To LB, Horvath N,. Assessment of early paraprotein response to vincristine-doxorubicin-dexamethasone chemotherapy may help guide therapy in multiple myeloma. Intern Med J. 2004; 34: 576-578. (Pubitemid 39482335)
- (2004) Internal Medicine Journal , vol.34 , Issue.9-10 , pp. 576-578
- Ross, D.M.¹ To, L.B.² Horvath, N.³

7
- 2042511646
- Early response to therapy and survival in multiple myeloma
- DOI 10.1111/j.1365-2141.2004.04884.x
- Schaar CG, Kluin-Nelemans JC, le Cessie S, et al. Early response to therapy and survival in multiple myeloma. Br J Haematol. 2004; 125: 162-166. (Pubitemid 38534967)
- (2004) British Journal of Haematology , vol.125 , Issue.2 , pp. 162-166
- Schaar, C.G.¹ Kluin-Nelemans, J.C.² Le Cessie, S.³ Franck, P.F.H.⁴ Te Marvelde, M.C.⁵ Wijermans, P.W.⁶

8
- 0032941715
- Posttreatment M-protein nadir level is a significant prognostic factor associated with survival in multiple myeloma
- Shimizu K, Kamiya O, Hirabayashi N, et al. Posttreatment M-protein nadir level is a significant prognostic factor associated with survival in multiple myeloma. Nagoya Myeloma Cooperative Study Group. Jpn J Cancer Res. 1999; 90: 355-360. (Pubitemid 29164027)
- (1999) Japanese Journal of Cancer Research , vol.90 , Issue.3 , pp. 355-360
- Shimizu, K.¹ Kamiya, O.² Hirabayashi, N.³ Ichikawa, A.⁴ Kawashima, K.⁵ Kobayashi, M.⁶ Mizuno, H.⁷ Nagura, E.⁸ Nitta, M.⁹ Saito, H.¹⁰ Sao, H.¹¹ Shibata, T.¹² Takeyama, H.¹³

9
- 0035431468
- Posttreatment nadir M-protein level is a stronger discriminator of survival following plateau attainment than is percent reduction in M-protein in patients with IgG myeloma
- Shimizu K, Nagura E, Hirabayashi N, et al. Posttreatment nadir M-protein level is a stronger discriminator of survival following plateau attainment than is percent reduction in M-protein in patients with IgG myeloma. Int J Hematol. 2001; 74: 205-208. (Pubitemid 33760073)
- (2001) International Journal of Hematology , vol.74 , Issue.2 , pp. 205-208
- Shimizu, K.¹ Nagura, E.² Hirabayashi, N.³ Wakita, A.⁴ Takeyama, H.⁵ Sao, H.⁶ Nitta, M.⁷ Kawashima, K.⁸ Saito, H.⁹

10
- 34547962120
- High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis
- DOI 10.1182/blood-2007-01-067728
- van Rhee F, Bolejack V, Hollmig K, et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood. 2007; 110: 827-832. (Pubitemid 47267417)
- (2007) Blood , vol.110 , Issue.3 , pp. 827-832
- Van Rhee, F.¹ Bolejack, V.² Hollmig, K.³ Pineda-Roman, M.⁴ Anaissie, E.⁵ Epstein, J.⁶ Shaughnessy Jr., J.D.⁷ Zangari, M.⁸ Tricot, G.⁹ Mohiuddin, A.¹⁰ Alsayed, Y.¹¹ Woods, G.¹² Crowley, J.¹³ Barlogie, B.¹⁴

11
- 33745801771
- Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone
- Jagannath S, Richardson PG, Barlogie B, et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica. 2006; 91: 929-934. (Pubitemid 44023146)
- (2006) Haematologica , vol.91 , Issue.7 , pp. 929-934
- Jagannath, S.¹ Richardson, P.G.² Barlogie, B.³ Berenson, J.R.⁴ Singhal, S.⁵ Irwin, D.⁶ Srkalovic, G.⁷ Schenkein, D.P.⁸ Esseltine, D.L.⁹ Anderson, K.C.¹⁰

12
- 34247516968
- Available at:. Accessed October 19
- NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™): Multiple Myeloma. v.1.2011. Available at:. Accessed October 19, 2010.
- (2010) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™): Multiple Myeloma. v.1.2011

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.